Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs Davita Inc — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.94, while Davita Inc trades at $179.08 (market cap $11.38B). Which is the better fit depends on your goals.
| BOTZ | DVA | |
|---|---|---|
52-Week High | $41.63 | $240.96 |
52-Week Low | $31.99 | $103.87 |
Market Cap | — | $11.38B |
Sector | — | Health |
Enterprise Value | — | $24.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $37.92, up 1.34% with a bullish technical signal supported by moving averages. The robotics and AI ETF shows strong momentum with key resistance at $38. Recent articles highlight BOTZ as the largest pure-play robotics fund, positioned to benefit from the shift from digital to physical AI applications. The fund offers exposure to global robotics leaders with a lower expense ratio than peers.
Outlook remains positive as robotics adoption accelerates globally, though overbought RSI signals near-term caution. Investment opportunity lies in AI's expansion into physical automation, while risks include sector concentration and valuation pressures in tech. The fund's global diversification provides exposure to non-US AI innovation.
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
